Documented Research Materials

Availability on request

Retatrutide (development code LY3437943) is a triple receptor agonist currently under development that targets GIP, GLP-1, and glucagon (GCG) receptors simultaneously. It is primarily being investigated for the treatment of obesity, overweight, and related metabolic diseases. Key advantage: significant weight loss.

Availability on request

Tirzepatide is a once-weekly GIP+GLP-1 dual receptor agonist currently used primarily to treat type 2 diabetes and to assist with weight management in obese or overweight individuals. Its mechanism of action includes enhancing satiety, suppressing appetite, and improving glycemic control. Key Benefits: Significant weight loss; reduced appetite and increased satiety; lower blood glucose levels and improved hemoglobin A1c (HbA1c) levels; improved certain metabolic markers;

Availability on request

Key Benefits of AICAR: Promotes glucose uptake by skeletal muscle, influences energy metabolism, and improves endurance,

Availability on request

Effects observed in the Adipotide study: weight and body fat loss, as well as improvements in metabolic markers

Availability on request

Semaglutide belongs to the class of GLP-1 receptor agonists and is primarily used to treat type 2 diabetes and obesity/overweight in specific populations. Its main benefits include: lowering blood glucose levels, suppressing appetite, aiding weight loss, reducing certain cardiovascular risks, and improving metabolic markers

Availability on request

AOD-9604 is a synthetic growth hormone (hGH) fragment peptide that was initially developed to harness the “fat-burning” effects of a portion of growth hormone while avoiding the growth and IGF-1-related effects associated with full-length growth hormone. Its promotional and research focus is on: promoting fat breakdown and fat oxidation, and fat loss/weight loss

Availability on request

MOTS-c (human MOTS-c) is a 16-amino acid peptide derived from mitochondria and belongs to the class of “mitochondria-derived peptides,” which have become a hot topic of research in recent years. It is associated with energy metabolism, insulin sensitivity, and exercise adaptation. Benefits and Effects: Improves insulin sensitivity and glucose metabolism; influences fat metabolism; promotes exercise adaptation and physical performance; exhibits anti-aging potential;

Availability on request

Mazdutide is a new-generation weight-loss drug that has garnered significant attention in recent years. Unlike semaglutide, it not only acts on GLP-1 but also simultaneously activates both the GLP-1 receptor and the glucagon receptor (GCG), and is therefore classified as a “dual receptor agonist.” Key benefits: Significant weight loss, reduced appetite, improved blood glucose levels, and improved certain metabolic markers